| 13.57 0.36 (2.73%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.51 | 1-year : | 20.53 |
| Resists | First : | 14.99 | Second : | 17.57 |
| Pivot price | 14.15 |
|||
| Supports | First : | 10.81 | Second : | 9 |
| MAs | MA(5) : | 13.26 |
MA(20) : | 14.34 |
| MA(100) : | 11.83 |
MA(250) : | 10.09 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 20.4 |
D(3) : | 17.5 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 17.57 | Low : | 5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DNA ] has closed above bottom band by 36.0%. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.71 - 13.77 | 13.77 - 13.83 |
| Low: | 13.14 - 13.19 | 13.19 - 13.26 |
| Close: | 13.46 - 13.56 | 13.56 - 13.66 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Fri, 24 Oct 2025
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating the Biotech Terrain Amidst Challenging Metrics - DirectorsTalk Interviews
Thu, 23 Oct 2025
Ginkgo Bioworks (NYSE: DNA) joins STRM.BIO, UBC on in vivo CAR-T for autoimmune diseases - Stock Titan
Wed, 22 Oct 2025
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Tue, 21 Oct 2025
Ginkgo Bioworks CFO Coen sells shares worth $17907 - Investing.com
Thu, 16 Oct 2025
Ginkgo Bioworks Holdings, Inc. (DNA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Thu, 09 Oct 2025
Ginkgo Bioworks Holdings, Inc. (DNA) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 79.1 (%) |
| Shares Short | 5,840 (K) |
| Shares Short P.Month | 6,710 (K) |
| EPS | -5.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.06 |
| Profit Margin | -136.6 % |
| Operating Margin | -124.8 % |
| Return on Assets (ttm) | -12.9 % |
| Return on Equity (ttm) | -43.6 % |
| Qtrly Rev. Growth | -11.7 % |
| Gross Profit (p.s.) | 3.87 |
| Sales Per Share | 4.9 |
| EBITDA (p.s.) | -4.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -238 (M) |
| Levered Free Cash Flow | -142 (M) |
| PE Ratio | -2.36 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 2.76 |
| Price to Cash Flow | -2.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|